Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.
Jing Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Bo Lan(Chinese Academy of Medical Sciences & Peking Union Medical College), Xuelian Chen(Chengdu Medical College), Dawei Wu(Nanjing University of Aeronautics and Astronautics), Lanying Ma(Xinjiang Medical University), Qing Yang(Guangzhou University of Chinese Medicine), Qu Dong(Chinese Academy of Medical Sciences & Peking Union Medical College), Hongnan Mo(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 9
Related Papers
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
|Nature Medicine|2023|541
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
|Signal Transduction and Targeted Therapy|2019|406
Sumoylation Promotes the Stability of the DNA Sensor cGAS and the Adaptor STING to Regulate the Kinetics of Response to DNA Virus
|Immunity|2016|378
Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
|Clinical Cancer Research|2018|218